Compare Incyte Corporation (INCY) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tidewater Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Tidewater Inc trades at $76.1 (market cap $3.75B). The key difference: Incyte Corporation is far larger — about 6.2× Tidewater Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals.
| INCY | TDW | |
|---|---|---|
Market Cap | $23.11B | $3.75B |
Sector | Health | Utilities |
52-Week High | $118.52 | $91.12 |
52-Week Low | $67.38 | $47.29 |
Enterprise Value | $19.13B | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical outlook supported by moving averages but recent earnings misses in Q1 and Q4 2026. The company maintains strong profitability with a 22.16% net margin and a P/E of 12.79, while news highlights an acquisition by FTAI Infrastructure (GlobeNewsWire, June 29, 2026).
Outlook is mixed: valuation appears reasonable with solid cash flow, but earnings volatility and sector headwinds pose risks. Analyst consensus leans hold (61.54%), suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
